Meeting
2022 ASCO Annual Meeting
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Authors
Frederick L. Locke
Moffitt Cancer Center, Tampa, FL
Frederick L. Locke , Justin Chou , Saran Vardhanabhuti , Regis Perbost , Peter Dreger , Brian T Hill , Catherine Lee , Pier Luigi Zinzani , Nicolaus Kroeger , Armando López-Guillermo , Hildegard Greinix , Wangshu Zhang , Gayatri Tiwari , Christina Ann To , Paul C. Cheng , Adrian Bot , Rhine Shen , Simone Filosto , Jerome Galon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03391466
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7565)
DOI
10.1200/JCO.2022.40.16_suppl.7565
Abstract #
7565
Poster Bd #
218
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma.
First Author: Marie José Kersten
Poster
2019 ASCO Annual Meeting
Outcomes in large B-cell lymphoma progressing after axicabtagene ciloleucel (Axi-cel): Results from the US lymphoma CAR-T consortium.
First Author: Jay Y. Spiegel
Poster
2023 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) by clonoSEQ to monitor residual disease after axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).
First Author: Brodie Miles
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.
First Author: Armin Ghobadi